Business, energy, technology, markets and global industry news from Business News Today

Jakafi XR

PharmaDeviceNews Jakafi XR
Representative image: A hematology clinician reviews treatment data in a clinical lab setting as Incyte’s FDA approval of once-daily Jakafi XR highlights the next phase of ruxolitinib therapy for myelofibrosis, polycythemia vera and graft-versus-host disease.
Pharma & Biotech

Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?

Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.

Read More